Ceribell Inc (CBLL)

NASD · Healthcare · Medical Devices · USA

Ceribell Inc is a small cap company (market value between $300 million and $2 billion) in the Medical Devices industry.

Ceribell is a medical technology company that develops the Ceribell System, a portable EEG platform for acute care settings. The system combines disposable wearables and a pocket-sized recorder with AI-powered algorithms to enable rapid seizure detection and continuous neurological monitoring by non-specialized healthcare professionals. Ceribell serves hospitals across the United States.

From its FY2025 annual report (Form 10-K)

Intrinsic value, DCF valuation, financial health and value investing analysis for the Ceribell Inc stock.

Our verdict on CBLL

Not valued: We cannot value this company yet.

We do not publish a value for this company: its filings cover three fiscal years and projecting growth needs four in a row.

ETFs with the most weight in CBLL

17 more funds hold it; the full list is part of the paid plan.

Browse

Peers in Medical Devices

All 140 Medical Devices stocks

Cheaper than CBLL in Medical Devices

61 more in this industry show a wider margin of safety.

Is CBLL undervalued or overvalued?

We do not publish a verdict on CBLL yet. A discounted cash flow projects five years of revenue, so it needs this company’s own growth history: four consecutive fiscal years of accounts, which give three year-on-year growth rates. Its filings on our archive cover three fiscal years so far; the next annual report should close the gap. We could plug in a generic rate, but that would be a valuation of an average company, not of this one.

What is the intrinsic value of CBLL?

We do not publish one (as of the 2026-11-17 close). A discounted cash flow projects five years of revenue, so it needs this company’s own growth history: four consecutive fiscal years of accounts, which give three year-on-year growth rates. Its filings on our archive cover three fiscal years so far; the next annual report should close the gap. We could plug in a generic rate, but that would be a valuation of an average company, not of this one.